Rhubarb in renal fibrosis: from traditional ethnopharmacology to mechanistic therapeutic development

Abstract

Rhubarb (Rheum spp.), a traditional herbal medicine, has attracted growing interest due to its anti-renal fibrosis effects in chronic kidney disease (CKD). This review systematically evaluates Rhubarb’s botanical features, global distribution, and diverse processing methods, which influence its chemical composition and bioactivity. Major bioactive constituents, including anthraquinones, stilbenes, and polyphenols, are cataloged, and their potential roles in renal protection are elucidated. Traditional applications in nephropathy management are critically assessed alongside contemporary pharmacological evidence demonstrating Rhubarb’s ability to attenuate renal fibrosis. Notably, this review highlights that multiple bioactive components in Rhubarb exert potent anti-fibrotic effects through complex, interactive modulation of multiple signaling pathways. Despite promising preclinical data, clinical translation remains limited by insufficient understanding of pharmacokinetics and potential herb-drug interactions. This synthesis identifies key research gaps, advocating for interdisciplinary studies to decipher multi-target mechanisms, refine pharmacokinetic profiles to enhance bioavailability, and translate preclinical findings into randomized controlled trials (RCTs). By integrating ethnopharmacological knowledge with modern drug discovery frameworks, this review underscores Rhubarb’s potential as a multifaceted anti-fibrotic agent while calling for methodologically rigorous research to validate its therapeutic integration into CKD management protocols.

Keywords

Rhubarb / Renal Fibrosis / Ethnopharmacology / Chemical components / Chronic kidney disease

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 82204746, 82003982), The 940th Hospital G-Project (Nos.2024-G3-7, 2024-G3-8), the Natural Science Foundation of Gansu Province (No. 25JRRA810), the Natural Science Foundation of Lanzhou (Nos. 2024-9-132; 2024-9-135), the Special Cultivation Project of the 940th Hospital (No. 2021yxky026), and the Major Science and Technology Projects of Gansu Province (No. 24ZDFA008).

Declaration of competing interests

The authors have no conflict of interest to declare.

References

[1] Levin A, Ahmed SB, Carrero JJ, et al.Executive summary of the KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024; 105(4):684-701. https://doi.org/10.1016/j.kint.2023.10.016.

[2] Roccatello D, Lan H, Sciascia S, et al. From inflammation to renal fibrosis: a one-way road in autoimmunity.? Autoimmun Rev. 2024; 23(4):103466. https://doi.org/10.1016/j.autrev.2023.103466.

[3] Lahane GP, Dhar A, Bhat A. Therapeutic approaches and novel antifibrotic agents in renal fibrosis: a comprehensive review. J Biochem Mol Toxicol. 2024; 38(8):e23795. https://doi.org/10.1002/jbt.23795.

[4] Liang L, Mi Y, Zhou S, et al. Advances in the study of key cells and signaling pathways in renal fibrosis and the interventional role of Chinese medicines. Front Pharmacol. 2024; 15:1403227. https://doi.org/10.3389/fphar.2024.1403227.

[5] Xiang H, Zuo J, Guo F, et al. What we already know about rhubarb: a comprehensive review. Chin Med. 2020; 15:88. https://doi.org/10.1186/s13020-020-00363-1.

[6] Zhu X, Deng Z, Cao Y, et al. Resveratrol prevents Drp1-mediated mitochondrial fission in the diabetic kidney through the PDE4D/PKA pathway. Phytother Res. 2023; 37(12):5916-5931. https://doi.org/10.1002/ptr.8004.

[7] Kumar A, Jugran AK, Bargali SS, et al. Ethno-medicinal uses, ecology, phytochemistry, biological activities, and conservation approaches for Himalayan Rhubarb species. Nat Prod Res. 2025;1-14. https://doi.org/10.1080/14786419.2024.2441171.

[8] Yang B, Zhang Z, Song J, et al. Interpreting the efficacy enhancement mechanism of Chinese medicine processing from a biopharmaceutic perspective. Chin Med. 2024; 19(1):14. https://doi.org/10.1186/s13020-024-00887-0.

[9] Wu X, Wang S, Lu J, et al. Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives. Chin Med. 2018; 13(1):4. https://doi.org/10.1186/s13020-018-0163-3.

[10] Sun J, Wu Y, Dong S, et al. Influence of the drying method on the bioactive compounds and pharmacological activities of rhubarb. J Sci Food Agric. 2018; 98(9):3551-3562. https://doi.org/10.1002/jsfa.8871.

[11] Zhang J, Zhou P, Xu Y, et al. Metabolic profile and dynamic characteristic of rhubarb during the in vitro biotransformation by human gut microbiota. Food Chem. 2022; 397:133840. https://doi.org/10.1016/j.foodchem.2022.133840.

[12] Zhang J, Fu Y, Li L, et al. Pharmacokinetic comparisons of major bioactive components after oral administration of raw and steamed rhubarb by UPLC-MS/MS. J Pharm Biomed Anal. 2019; 171:43-51. https://doi.org/10.1016/j.jpba.2019.04.002.

[13] Liu T, Yu M, Dai Y, et al. Traditional method of rhubarb processing optimized by combining flavor analysis with anthraquinone content determination. Front Nutr. 2024; 11:1406430. https://doi.org/10.3389/fnut.2024.1406430.

[14] Zhou P, Zhang J, Xu Y, et al. Simultaneous quantification of anthraquinone glycosides, aglycones, and glucuronic acid metabolites in rat plasma and tissues after oral administration of raw and steamed rhubarb in blood stasis rats by UHPLC-MS/MS. J Sep Sci. 2022; 45(2):529-541. https://doi.org/10.1002/jssc.202100623.

[15] Zhu T, Liu X, Wang X, et al. Profiling and analysis of multiple compounds in rhubarb decoction after processing by wine steaming using UHPLC-Q-TOF-MS coupled with multiple statistical strategies. J Sep Sci. 2016; 39(15):3081-3090. https://doi.org/10.1002/jssc.201600256.

[16] Wang M, Fu J, Lv M, et al. Effect of wine processing and acute blood stasis on the serum pharmacochemistry of rhubarb: a possible explanation for processing mechanism. J Sep Sci. 2014; 37(18):2499-2503. https://doi.org/10.1002/jssc.201400473.

[17] Ma J, Meng X, Guo X, et al. Thermal analysis during partial carbonizing process of rhubarb, moutan and burnet. PLoS One. 2017; 12(3):e0173946. https://doi.org/10.1371/journal.pone.0173946.

[18] Yang L, Yang L, Pei W, et al. Color-reflected chemical regulations of the scorched rhubarb (Rhei Radix et Rhizoma) revealed by the integration analysis of visible spectrophotometry, fourier transform infrared spectroscopy and high performance liquid chromatography. Food Chem. 2022; 367:130730. https://doi.org/10.1016/j.foodchem.2021.130730.

[19] Zhong L, Sun J, Li S, et al. Scorch processing of rhubarb (Rheum tanguticum Maxim. ex Balf.) pyrolyzed anthraquinone glucosides into aglycones and improved the therapeutic effects on thromboinflammation via regulating the complement and coagulation cascades pathway. J Ethnopharmacol. 2024; 333:118475. https://doi.org/10.1016/j.jep.2024.118475.

[20] Zhang Q, Chen Y, Yue S, et al. Study on the content changes of 16 chemical components in Radix et Rhizoma Rhei and its different processed products. China J Tradit Chin Med Pharm. 2022; 37(2):1036-1044. https://doi.org/10.4266/cissn.1672-2779.2022.0204.

[21] Xin L, Jing X, Li H, et al. Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and meta-analysis. J Tradit Chin Med. 2023; 43(3):429-440. https://doi.org/10.1016/j.jtcm.2023.03.003.

[22] Zhang F, Wu R, Liu Y, et al. Nephroprotective and nephrotoxic effects of rhubarb and their molecular mechanisms. Biomed Pharmacother. 2023; 160:114297. https://doi.org/10.1016/j.biopha.2023.114297.

[23] Gao H, He C, Xin S, et al. Rhubarb extract rebuilding the mucus homeostasis and regulating mucin-associated flora to relieve constipation. Exp Biol Med (Maywood). 2023; 248(23):2449-2463. https://doi.org/10.1177/15353702231218594.

[24] Neyrinck AM, Rodriguez J, Taminiau B, et al. Constipation mitigation by rhubarb extract in middle-aged adults is linked to gut microbiome modulation: a double-blind randomized placebo-controlled trial. Int J Mol Sci. 2022; 23(23):14685. https://doi.org/10.3390/ijms232314685.

[25] Luo Y, Feng X, Wu D, et al. A randomized controlled trial of Chinese traditional medicine Dachengqi Decoction in the treatment of postoperative intestinal function recovery. Transl Cancer Res. 2020; 9(8):4498-4506. https://doi.org/10.21037/tcr-19-2671.

[26] Khiveh A, Hashempur MH, Shakiba M, et al.Effects of rhubarb (Rheum ribes L.) syrup on dysenteric diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Integr Med. 2017; 15(5):365-372. https://doi.org/10.1016/S2095-4964(17)60344-3.

[27] Zhuang T, Gu X, Zhou N, et al. Hepatoprotection and hepatotoxicity of Chinese herb rhubarb (Dahuang): how to properly control the “General (Jiang Jun)” in Chinese medical herb. Biomed Pharmacother. 2020; 127:110224. https://doi.org/10.1016/j.biopha.2020.110224.

[28] Liu W, Tu Z, Liu J, et al. Therapeutic effect of Yinchenhao Decoction on cholelithiasis via mucin in the gallbladder and intestine. Fitoterapia. 2024; 172:105746. https://doi.org/10.1016/j.fitote.2023.105746.

[29] Luo S, Huang M, Lu X, et al. Optimized therapeutic potential of Yinchenhao Decoction for cholestatic hepatitis by combined network meta-analysis and network pharmacology. Phytomedicine. 2024; 129:155573. https://doi.org/10.1016/j.phymed.2024.155573.

[30] Wang L, Wang H, Niu J, et al. Cholesterol-lowering effects of rhubarb free anthraquinones and their mechanism of action. Eur J Pharmacol. 2024; 966:176348. https://doi.org/10.1016/j.ejphar.2024.176348.

[31] Zhang F, Wu R, Liu Y, et al. Integration of pharmacodynamics and metabolomics to reveal rhubarb anthraquinone protection against nonalcoholic fatty liver disease rat model. J Pharm Pharmacol. 2024; 76(4):381-390. https://doi.org/10.1093/jpp/rgae014.

[32] Wan Y, Sun S, Fu H, et al. Adjuvant rhubarb alleviates organs dysfunction and inhibits inflammation in heat stroke. Exp Ther Med. 2018; 16(2):1493-1498. https://doi.org/10.3892/etm.2018.6344.

[33] Huang QJ, Wang MY, Wang M, et al. Scutellaria baicalensis: a promising natural source of antiviral compounds for the treatment of viral diseases. Chin J Nat Med. 2023; 21(8):563-575. https://doi.org/10.1016/S1875-5364(23)60401-7.

[34] Cai Z, Li S, Wang Y. Integrated serum pharmacochemistry, network pharmacology, and molecular docking to study the mechanism of rhubarb against atherosclerosis. Curr Pharm Biotechnol. 2025; 26(4):564-575.https://doi.org/10.2174/0113892010296117240531071301.

[35] Khan IA, Nasiruddin M, Haque SF, et al. Evaluation of rhubarb supplementation in stages 3 and 4 of chronic kidney disease: a randomized clinical trial. Int J Chron Dis. 2014; 2014:485960. https://doi.org/10.1155/2014/485960.

[36] Li S, Du S, Du Z, et al. Distribution of Traditional Chinese Medicine syndromes in diabetic kidney disease chronic kidney disease 1-5: a correlation study. J Tradit Chin Med. 2024; 44(3):572-580. https://doi.org/10.1016/j.jtcm.2024.02.002.

[37] Cao Y, Pu Z, Tang Y, et al. Advances in bio-active constituents, pharmacology and clinical applications of rhubarb. Chin Med. 2017; 12:36. https://doi.org/10.1186/s13020-017-0144-6.

[38] Xu H, Wang W, Li X, et al. Botany, traditional use, phytochemistry, pharmacology and clinical applications of rhubarb (Rhei Radix et Rhizoma): a systematic review. Am J Chin Med. 2024; 52(7):1925-1967. https://doi.org/10.1142/S0192415X24500757.

[39] Huang W, Rao Y, Li L, et al. Clinical effect of rhubarb on the treatment of chronic renal failure: a meta-analysis. Front Pharmacol. 2023; 14:1108861. https://doi.org/10.3389/fphar.2023.1108861.

[40] Xiang Z, Sun H, Cai X, et al. The study on the material basis and the mechanism for anti-renal interstitial fibrosis efficacy of rhubarb through integration of metabonomics and network pharmacology. Mol Biosyst. 2015; 11(4):1067-1078. https://doi.org/10.1039/C4MB00573B.

[41] Qin MY, Huang SQ, Zou XQ, et al. Drug-containing serum of rhubarb-astragalus capsule inhibits the epithelial-mesenchymal transformation of HK-2 by downregulating TGF-β1/p38MAPK/Smad2/ 3 pathway. J Ethnopharmacol. 2021; 280:114414. https://doi.org/10.1016/j.jep.2021.114414.

[42] Zeng X, Cai G, Liang T, et al. Rhubarb and astragalus capsule attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction by alleviating apoptosis through regulating transforming growth factor beta1 (TGF-β1)/p38 mitogen-activated protein kinases (p38 MAPK) pathway. Med Sci Monit. 2020; 26:e920720. https://doi.org/10.12659/MSM.920720.

[43] Zhang Q, Ye X, Zhu L, et al. Spatiotemporal delivery of multiple components of rhubarb-astragalus formula for the synergistic treatment of renal fibrosis. Front Pharmacol. 2024; 15:1456721. https://doi.org/10.3389/fphar.2024.1456721.

[44] Haq SM, Khoja AA, Lone FA, et al. Keeping healthy in your skin—plants and fungi used by indigenous Himalayan communities to treat dermatological ailments. Plants. 2023; 12(7):1575. https://doi.org/10.3390/plants12071575.

[45] Tang T, Yin L, Yang J, et al. Emodin, an anthraquinone derivative from Rheum officinale Baill, enhances cutaneous wound healing in rats. Eur J Pharmacol. 2007; 567(3):177-185. https://doi.org/10.1016/j.ejphar.2007.02.033.

[46] Ebert T, Pawelzik S, Witasp A, et al. Inflammation and premature ageing in chronic kidney disease. Toxins. 2020; 12(4):227. https://doi.org/10.3390/toxins12040227.

[47] Zoccali C, Mallamaci F, Kanbay M, et al. The autonomic nervous system and inflammation in chronic kidney disease. Nephrol Dial Transplant. 2025; 40(8):1470-1482. https://doi.org/10.1093/ndt/gfaf020.

[48] Zhu Y, Yang S, Lv L, et al. Research progress on the positive and negative regulatory effects of rhein on the kidney: a review of its molecular targets. Molecules. 2022; 27(19):6572. https://doi.org/10.3390/molecules27196572.

[49] Xiong W, Tang J, Yu H, et al. Emodin inhibits M1 macrophage activation that related to acute and chronic kidney injury through EGFR/MAPK pathway. Funct Integr Genomics. 2024; 24(4):131. https://doi.org/10.1007/s10142-024-01327-8.

[50] Sun L, Han Y, Shen C, et al. Emodin alleviates high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation of mesangial cells by the circ_0000064/miR-30c-5p/Lmp 7 axis. J Recept Signal Transduct Res. 2022; 42(3):302-312. https://doi.org/10.1080/10799893.2021.1933028.

[51] Ji J, Tao P, Wang Q, et al.Emodin attenuate diabetic kidney disease by inhibiting ferroptosis via up regulating Nrf2 expression. Aging (Albany NY). 2023; 15(15):7673-7688. https://doi.org/10.18632/aging.205984.

[52] Zhu Y, Jin H, Huo X, et al. Protective effect of rhein against vancomycin-induced nephrotoxicity through regulating renal transporters and Nrf 2 pathway. Phytother Res. 2022; 36(11):4244-4262. https://doi.org/10.1002/ptr.7559.

[53] Njeim R, Merscher S, Fornoni A. Mechanisms and implications of podocyte autophagy in chronic kidney disease. Am J Physiol Renal Physiol. 2024; 326(6):F877-F893. https://doi.org/10.1152/ajprenal.00415.2023.

[54] Ruby M, Gifford CC, Pandey R, et al. Autophagy as a therapeutic target for chronic kidney disease and the roles of TGF-β1 in autophagy and kidney fibrosis. Cells. 2023; 12(3):412. https://doi.org/10.3390/cells12030412.

[55] Tu Y, Gu L, Chen D, et al. Rhein inhibits autophagy in rat renal tubular cells by regulation of AMPK/mTOR signaling. Sci Rep. 2017; 7(1):43790. https://doi.org/10.1038/srep43790.

[56] Katuri A, Bryant J, Patel D, et al. HIVAN associated tubular pathology with reference to ER stress, mitochondrial changes, and autophagy. Exp Mol Pathol. 2019; 106:139-148. https://doi.org/10.1016/j.yexmp.2018.12.009.

[57] Li J, Qin X, Xu W, et al. Herb pair of rhubarb-astragalus mitigates renal interstitial fibrosis through downregulation of autophagy via p38-MAPK/TGF-β1 and p38-MAPK/smad2/ 3 pathways. Int J Biochem Cell Biol. 2024; 169:106549. https://doi.org/10.1016/j.biocel.2024.106549.

[58] Xiong D, Hu W, Han X, et al. Rhein inhibited ferroptosis and EMT to attenuate diabetic nephropathy by regulating the Rac1/NOX1/β-catenin axis. Front Biosci (Landmark Ed). 2023; 28(5):100. https://doi.org/10.31083/j.fbl2805100.

[59] HaoShang, Jia X, Liu H, et al. A comprehensive review of emodin in fibrosis treatment. Fitoterapia. 2023; 165:105358. https://doi.org/10.1016/j.fitote.2022.105358.

[60] Tsuji K, Uchida N, Nakanoh H, et al. The gut-kidney axis in chronic kidney diseases. Diagnostics. 2025; 15(1):21. https://doi.org/10.3390/diagnostics15010021.

[61] Ji C, Li Y, Mo Y, et al. Rhubarb enema decreases circulating trimethylamine N-oxide level and improves renal fibrosis accompanied with gut microbiota change in chronic kidney disease rats. Front Pharmacol. 2021; 12:780924. https://doi.org/10.3389/fphar.2021.780924.

[62] Ji C, Lu F, Wu Y, et al. Rhubarb enema increasing short-chain fatty acids that improves the intestinal barrier disruption in CKD may be related to the regulation of gut dysbiosis. Biomed Res Int. 2022; 2022:1896781. https://doi.org/10.1155/2022/1896781.

[63] Li XJ, Shan QY, Wu X, et al. Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis. Cell Mol Life Sci. 2024; 81(1):480. https://doi.org/10.1007/s00018-024-05532-5.

[64] Reiss AB, Jacob B, Zubair A, et al. Fibrosis in chronic kidney disease: pathophysiology and therapeutic targets. J Clin Med. 2024; 13(7):1881. https://doi.org/10.3390/jcm13071881.

[65] Deng Z, Fan T, Xiao C, et al.TGF-β signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024; 9(1):61. https://doi.org/10.1038/s41392-024-01764-w.

[66] Lathan R. Exploring unconventional targets in myofibroblast transdifferentiation outside classical TGF-β signaling in renal fibrosis. Front Physiol. 2024; 15:1296504. https://doi.org/10.3389/fphys.2024.1296504.

[67] Soudeh G, Arian A, Hamed S, et al. Antioxidant therapy against TGF-β/SMAD pathway involved in organ fibrosis. J Cell Mol Med. 2023; 28(2):e18052. https://doi.org/10.1111/jcmm.18052.

[68] Liu W, Hu C, Qian X, et al. TaoHeChengQi Decoction alleviate chronic renal failure via regulation of PHD2/UCP1 and RIPK3/AKT/TGF-β pathway. Phytomedicine. 2025; 141:156548. https://doi.org/10.1016/j.phymed.2025.156548.

[69] Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1):3. https://doi.org/10.1038/s41392-021-00762-6.

[70] Qin K, Yu M, Fan J, et al. Canonical and noncanonical Wnt signaling: multilayered mediators, signaling mechanisms and major signaling crosstalk. Genes Dis. 2023; 11(1):103-134. https://doi.org/10.1016/j.gendis.2022.11.013.

[71] Somanander DVN, Zhao P, Widdop RE, et al. The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin. Biochem Pharmacol. 2024; 223:116130. https://doi.org/10.1016/j.bcp.2024.116130.

[72] Duan S, Wu Y, Zhao C, et al. The Wnt/β-catenin signaling pathway participates in rhein ameliorating kidney injury in DN mice. Mol Cell Biochem. 2016; 411(1-2):73-82. https://doi.org/10.1007/s11010-015-2569-x.

[73] Lv Y, Pang X, Cao Z, et al. Evolution and function of the Notch signaling pathway: an invertebrate perspective. Int J Mol Sci. 2024; 25(6):3322. https://doi.org/10.3390/ijms25063322.

[74] Mukherjee M, Fogarty E, Janga M, et al. Notch signaling in kidney development, maintenance, and disease. Biomolecules. 2019; 9(11):692. https://doi.org/10.3390/biom9110692.

[75] Asanuma K, Trejo JO, Tanaka E. The role of Notch signaling in kidney podocytes. Clin Exp Nephrol. 2017; 21(1):1-6. https://doi.org/10.1007/s10157-016-1247-y.

[76] Xia Z, Wang J, Yang S, et al. Emodin alleviates hypertrophic scar formation by suppressing macrophage polarization and inhibiting the Notch and TGF-β pathways in macrophages. Braz J Med Biol Res. 2021; 54(8):e11184. https://doi.org/10.1590/1414-431x2021e11184.

[77] Hu Y, Peng L, Zhuo X, et al. Resveratrol promotes diabetic wound healing by inhibiting Notch pathway. J Surg Res. 2024; 297:63-70. https://doi.org/10.1016/j.jss.2024.02.004.

[78] Hu Y, Peng L, Zhuo X, et al. Hedgehog signaling pathway in fibrosis and targeted therapies. Biomolecules. 2024; 14(12):1485. https://doi.org/10.3390/biom14121485.

[79] Greenberg D, D’Cruz R, Lacanlale JL, et al. Hedgehog-GLI mediated control of renal formation and malformation. Front Nephrol. 2023; 3:1176347. https://doi.org/10.3389/fneph.2023.1176347.

[80] Bai Y, Lu H, Lin C, et al. Sonic hedgehog-mediated epithelial-mesenchymal transition in renal tubulointerstitial fibrosis. Int J Mol Med. 2016; 37(5):1317-1327. https://doi.org/10.3892/ijmm.2016.2546.

[81] Bai Y, Lu H, Wu C, et al. Resveratrol inhibits epithelial-mesenchymal transition and renal fibrosis by antagonizing the hedgehog signaling pathway. Biochem Pharmacol. 2014; 92(3):484-493. https://doi.org/10.1016/j.bcp.2014.09.002.

[82] Wang T, Liu B, Huang J, et al. IFN-γ-mediated inhibition of JAK/STAT signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis. J Transl Med. 2025; 23(1):195. https://doi.org/10.1186/s12967-025-06155-5.

[83] Liu J, Wang F, Luo F. The role of JAK/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules. 2023; 13(1):119. https://doi.org/10.3390/biom13010119.

[84] Chuang PY, He JC.JAK/STAT signaling in renal diseases. Kidney Int. 2010; 78(3):231-234. https://doi.org/10.1038/ki.2010.158.

[85] Shim K, Song HK, Park M, et al. Reynoutria japonica consisted of emodin-8-β-D-glucoside ameliorates Dermatophagoides farinae extract-induced atopic dermatitis-like skin inflammation in mice by inhibiting JAK/STAT signaling. Biomed Pharmacother. 2024; 176:116765. https://doi.org/10.1016/j.biopha.2024.116765.

[86] Lao Z, Chen X, Pan B, et al. Pharmacological regulators of Hippo pathway: advances and challenges of drug development. FASEB J. 2025; 39(6):e70438. https://doi.org/10.1096/fj.202401895RR.

[87] Sun Y, Jin D, Zhang Z, et al. The critical role of the Hippo signaling pathway in kidney diseases. Front Pharmacol. 2022; 13:988175. https://doi.org/10.3389/fphar.2022.988175.

[88] Zhao C, Wang H, Xu C, et al. The critical role of the Hippo signaling pathway in renal fibrosis. Cell Signal. 2025; 130:111661. https://doi.org/10.1016/j.cellsig.2025.111661.

[89] Lee EH, Baek SY, Park JY, et al. Emodin in Rheum undulatum inhibits oxidative stress in the liver via AMPK with Hippo/Yap signalling pathway. Pharm Biol. 2020; 58(1):333-341. https://doi.org/10.1080/13880209.2020.1750658.

[90] Niculae A, Gherghina M, Peride I, et al. Pathway from acute kidney injury to chronic kidney disease: molecules involved in renal fibrosis. Int J Mol Sci. 2023; 24(18):14019. https://doi.org/10.3390/ijms241814019.

[91] Wang Z, Cheng Y, Su W, et al. Organ specific differences in alteration of aquaporin expression in rats treated with sennoside A, senna anthraquinones and rhubarb anthraquinones. Int J Mol Sci. 2021; 22(15):8026. https://doi.org/10.3390/ijms22158026.

[92] Khatoon M, Dubey A, Km VJ. Unveiling anthraquinones: diverse health benefits of an essential secondary metabolite. Recent Pat Biotechnol. 2025; 19(3):179-197. https://doi.org/10.2174/0118722083301761240628083511.

[93] Zhang M, Gong Z, Zhao Q, et al. Time-dependent laxative effect of sennoside A, the core functional component of rhubarb, is attributed to gut microbiota and aquaporins. J Ethnopharmacol. 2023; 311:116431. https://doi.org/10.1016/j.jep.2023.116431.

[94] Chan YL, Tang SN, Osman CP, et al. Exploring naphthoquinone and anthraquinone derivatives as antibiotic adjuvants against Staphylococcus aureus biofilms: synergistic effects of menadione. Microb Pathog. 2024; 195:106886. https://doi.org/10.1016/j.micpath.2024.106886.

[95] Lin C, Chuang S, Huang T, et al. A systematic comparison of the effect of topically applied anthraquinone aglycones to relieve psoriasiform lesion: the evaluation of percutaneous absorption and anti-inflammatory potency. Biomed Pharmacother. 2022; 145:112482. https://doi.org/10.1016/j.biopha.2021.112482.

[96] Chen Z, Xu Z, Chen X, et al. Characterization of five natural anthraquinone compounds as potent inhibitors against CYP1B1: implications for cancer treatment. Curr Drug Metab. 2024; 25(9):677-684. https://doi.org/10.2174/0113892002329282250108163208.

[97] Feng L, Lin Z, Tang Z, et al. Emodin improves renal fibrosis in chronic kidney disease by regulating mitochondrial homeostasis through the mediation of peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α.). Eur J Histochem. 2024; 68(2):3917. https://doi.org/10.4081/ejh.2024.3917.

[98] Liu W, Gu R, Lou Y, et al. Emodin-induced autophagic cell death hinders epithelial-mesenchymal transition via regulation of BMP-7/TGF-β1 in renal fibrosis. J Pharmacol Sci. 2021; 146(4):216-225. https://doi.org/10.1016/j.jphs.2021.03.009.

[99] Ma L, Li H, Zhang S, et al. Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2. Int Urol Nephrol. 2018; 50(2):373-382. https://doi.org/10.1007/s11255-017-1757-x.

[100] Yang F, Deng L, Li J, et al. Emodin retarded renal fibrosis through regulating HGF and TGFβ-Smad signaling pathway. Drug Des Devel Ther. 2020; 14:3567-3575. https://doi.org/10.2147/DDDT.S245847.

[101] Dou F, Liu Y, Liu L, et al. Aloe-emodin ameliorates renal fibrosis via inhibiting PI3K/Akt/mTOR signaling pathway in vivo and in vitro. Rejuvenation Res. 2019; 22(3):218-229. https://doi.org/10.1089/rej.2018.2104.

[102] Wang L, Yu X, Li H, et al. Cell and rat serum, urine and tissue metabolomics analysis elucidates the key pathway changes associated with chronic nephropathy and reveals the mechanism of action of rhein. Chin Med. 2023; 18(1):158. https://doi.org/10.1186/s13020-023-00862-1.

[103] Xiao Q, Yu X, Yu X, et al. An integrated network pharmacology and cell metabolomics approach to reveal the role of rhein, a novel PPARα agonist, against renal fibrosis by activating the PPARα-CPT1A axis. Phytomedicine. 2022; 102:154147. https://doi.org/10.1016/j.phymed.2022.154147.

[104] Song X, Du Z, Yao Z, et al. Rhein improves renal fibrosis by restoring Cpt1a-mediated fatty acid oxidation through SirT1/STAT3/twist1 pathway. Molecules. 2022; 27(7):2344. https://doi.org/10.3390/molecules27072344.

[105] Feng HY, Wang YQ, Yang J, et al. Anthraquinones from Rheum officinale ameliorate renal fibrosis in acute kidney injury and chronic kidney disease. Drug Des Devel Ther. 2025; 19:5739-5760. https://doi.org/10.2147/DDDT.S521265.

[106] Chen Y, Mu L, Xing L, et al. Rhein alleviates renal interstitial fibrosis by inhibiting tubular cell apoptosis in rats. Biol Res. 2019; 52(1):50. https://doi.org/10.1186/s40659-019-0257-0.

[107] Zhang Q, Yin S, Liu L, et al. Rhein reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal fibrosis in mice. Sci Rep. 2016; 6(1):34597. https://doi.org/10.1038/srep34597.

[108] Dou F, Ding Y, Wang C, et al. Chrysophanol ameliorates renal interstitial fibrosis by inhibiting the TGF-beta/Smad signaling pathway. Biochem Pharmacol. 2020; 180:114079. https://doi.org/10.1016/j.bcp.2020.114079.

[109] Gu M, Zhou Y, Liao N, et al. Chrysophanol, a main anthraquinone from Rheum palmatum L. (rhubarb), protects against renal fibrosis by suppressing NKD2/NF-κB pathway. Phytomedicine. 2022; 105:154381. https://doi.org/10.1016/j.phymed.2022.154381.

[110] Wei Q, Gao F, Gao L, et al. Construction of chrysophanol loaded nanoparticles with N-octyl-O-sulfate chitosan for enhanced nephroprotective effect. Eur J Pharm Sci. 2023; 193:106685. https://doi.org/10.1016/j.ejps.2023.106685.

[111] Zhou L, Cai X, Wang Y, et al. Chemistry and biology of natural stilbenes: an update. Nat Prod Rep. 2025; 19;42(2):359-405. https://doi.org/10.1039/d4np00033a.

[112] Teka T, Zhang L, Ge X, et al. Stilbenes: source plants, chemistry, biosynthesis, pharmacology, application and problems related to their clinical application—a comprehensive review. Phytochemistry. 2022; 197:113128. https://doi.org/10.1016/j.phytochem.2022.113128.

[113] Wiciński M, Erdmann J, Nowacka A, et al. Natural phytochemicals as SIRT activators—focus on potential biochemical mechanisms. Nutrients. 2023; 15(16):3578. https://doi.org/10.3390/nu15163578.

[114] Shazmeen, Haq IU, Rajoka MSR, et al. Role of stilbenes against insulin resistance: a review. Food Sci Nutr. 2021; 9(11):6389-6405. https://doi.org/10.1002/fsn3.2620.

[115] Regnier M, Van Hul M, Roumain M, et al. Inulin increases the beneficial effects of rhubarb supplementation on high-fat high-sugar diet-induced metabolic disorders in mice: impact on energy expenditure, brown adipose tissue activity, and microbiota. Gut Microbes. 2023; 15(1):2178796. https://doi.org/10.1080/19490976.2023.2178796.

[116] Begh MZA, Khan J, Zehravi M, et al. Targeting neurological disorders with stilbenes: bridging the preclinical-clinical gap. Int J Biol Sci. 2024; 20(14):5474-5494. https://doi.org/10.7150/ijbs.102032.

[117] Zhang X, Lu H, Xie S, et al. Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation-related signalling pathways. Br J Pharmacol. 2019; 176(24):4745-4759. https://doi.org/10.1111/bph.14842.

[118] Wang R, Yuan W, Li L, et al. Resveratrol ameliorates muscle atrophy in chronic kidney disease via the axis of SIRT1/FoxO1. Phytother Res. 2022; 36(8):3265-3275. https://doi.org/10.1002/ptr.7499.

[119] He T, Xiong J, Nie L, et al. Resveratrol inhibits renal interstitial fibrosis in diabetic nephropathy by regulating AMPK/NOX4/ROS pathway. J Mol Med (Berl). 2016; 94(12):1359-1371. https://doi.org/10.1007/s00109-016-1451-y.

[120] Xiao Z, Chen C, Meng T, et al. Resveratrol attenuates renal injury and fibrosis by inhibiting transforming growth factor-β pathway on matrix metalloproteinase 7. Exp Biol Med (Maywood). 2016; 241(2):140-146. https://doi.org/10.1177/1535370215598401.

[121] Liu S, Zhao M, Zhou Y, et al. Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: a potential risk to individuals with impaired kidney function. Phytomedicine. 2019; 57:223-235. https://doi.org/10.1016/j.phymed.2018.12.024.

[122] Choi SY, Piao ZH, Jin L, et al. Piceatannol attenuates renal fibrosis induced by unilateral ureteral obstruction via downregulation of histone deacetylase 4/ 5 or p38-MAPK signaling. PLoS One. 2016; 11(11):e0167340. https://doi.org/10.1371/journal.pone.0167340.

[123] Shen N, Wang T, Gan Q, et al. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity. Food Chem. 2022; 383:132531. https://doi.org/10.1016/j.foodchem.2022.132531.

[124] Cao X, Shang Y, Kong W, et al. Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways. J Ethnopharmacol. 2022; 284:114740. https://doi.org/10.1016/j.jep.2021.114740.

[125] Huang M, Xie X, Yuan R, et al. The multifaceted anti-atherosclerotic properties of herbal flavonoids: a comprehensive review. Pharmacol Res. 2025; 211:107551. https://doi.org/10.1016/j.phrs.2024.107551.

[126] Iheanacho MS, Kandel R, Roy P, et al. Epigallocatechin-3-gallate attenuates arsenic-induced fibrogenic changes in human kidney epithelial cells through reversal of epigenetic aberrations and antioxidant activities. Biofactors. 2023; 50(3):542-557. https://doi.org/10.1002/biof.1883.

[127] He C, Wang D, Wang R, et al. Epigallocatechin gallate induces the demethylation of actinin alpha 4 to inhibit diabetic nephropathy renal fibrosis via the NF-κB signaling pathway in vitro. Dose Response. 2022; 20(2):155932582211057. https://doi.org/10.1177/155932582211057.

[128] Kanlaya R, Kapincharanon C, Fong-Ngern K, et al. Induction of mesenchymal-epithelial transition (MET) by epigallocatechin-3-gallate to reverse epithelial-mesenchymal transition (EMT) in SNAI1-overexpressed renal cells: a potential anti-fibrotic strategy. J Nutr Biochem. 2022; 107:109066. https://doi.org/10.1016/j.jnutbio.2022.109066.

[129] Kanlaya R, Peerapen P, Nilnumkhum A, et al. Epigallocatechin-3-gallate prevents TGF-β1-induced epithelial-mesenchymal transition and fibrotic changes of renal cells via GSK-3β/β-catenin/Snail1 and Nrf 2 pathways. J Nutr Biochem. 2020; 76:108266. https://doi.org/10.1016/j.jnutbio.2019.108266.

[130] Wang Y, Liu N, Su X, et al. Epigallocatechin-3-gallate attenuates transforming growth factor-β1 induced epithelial-mesenchymal transition via Nrf2 regulation in renal tubular epithelial cells. Biomed Pharmacother. 2015; 70:260-267. https://doi.org/10.1016/j.biopha.2015.02.004.

[131] Wang Y, Wang B, Du F, et al. Epigallocatechin-3-gallate attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis in mice. J Histochem Cytochem. 2015; 63(4):270-279. https://doi.org/10.1369/0022155414568294.

[132] Wang Y, Liu N, Bian X, et al. Epigallocatechin-3-gallate reduces tubular cell apoptosis in mice with ureteral obstruction. J Surg Res. 2015; 197(1):145-154. https://doi.org/10.1016/j.jss.2015.03.034.

[133] Nagavally R, Sunilkumar S, Akhtar M, et al. Chrysin ameliorates cyclosporine-A-induced renal fibrosis by inhibiting TGF-β-induced epithelial-mesenchymal transition. Int J Mol Sci. 2021; 22(19):10252. https://doi.org/10.3390/ijms221910252.

[134] Kang M, Park S, Choi Y, et al. Chrysin inhibits diabetic renal tubulointerstitial fibrosis through blocking epithelial to mesenchymal transition. J Mol Med (Berl). 2015; 93(7):759-772. https://doi.org/10.1007/s00109-015-1301-3.

[135] Kang Y, Park S, Sim YE, et al. Highly water-soluble diacetyl chrysin ameliorates diabetes-associated renal fibrosis and retinal microvascular abnormality in db/db mice. Nutr Res Pract. 2023; 17(3):421. https://doi.org/10.4162/nrp.2023.17.3.421.

[136] Li F, Wei R, Huang M, et al. Luteolin can ameliorate renal interstitial fibrosis-induced renal anaemia through the SIRT1/FOXO3 pathway. Food Funct. 2022; 13(22):11896-11914. https://doi.org/10.1039/D2FO02477B.

[137] Wang Q, Wang F, Li X, et al. Quercetin inhibits the amphiregulin/EGFR signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in obstructive nephropathy. Phytother Res. 2023; 37(1):111-123. https://doi.org/10.1002/ptr.7670.

[138] Ma Z, Wang F, Wang H, et al. Quercetin ameliorates renal tubulointerstitial transformation and renal fibrosis by regulating NLRP3 in obstructive nephropathy. Minerva Med. 2023; 114(4):530-532. https://doi.org/10.23736/S0026-4806.22.08373-8.

[139] Chen H, Chiang Y, Hong Y, et al. Quercetin ameliorates renal injury and pyroptosis in lupus nephritis through inhibiting IL-33/ST2 pathway in vitro and in vivo. Antioxidants. 2022; 11(11):2238. https://doi.org/10.3390/antiox11112238.

[140] Guo X, Wen S, Wang J, et al. Senolytic combination of dasatinib and quercetin attenuates renal damage in diabetic kidney disease. Phytomedicine. 2024; 130:155705. https://doi.org/10.1016/j.phymed.2024.155705.

[141] Sánchez-Jaramillo EA, Gasca-Lozano LE, Vera-Cruz JM, et al. Nanoparticles formulation improves the antifibrogenic effect of quercetin on an adenine-induced model of chronic kidney disease. Int J Mol Sci. 2022; 23(10):5392. https://doi.org/10.3390/ijms23105392.

[142] Tu H, Ma D, Luo Y, et al. Quercetin alleviates chronic renal failure by targeting the PI3k/Akt pathway. Bioengineered. 2021; 12(1):6538-6558. https://doi.org/10.1080/21655979.2021.1973877.

[143] Liu T, Yang Q, Zhang X, et al. Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the SIRT1/PINK1/mitophagy axis. Life Sci. 2020; 257:118116. https://doi.org/10.1016/j.lfs.2020.118116.

[144] Han Y, Lu J, Xu Y, et al. Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling. Int J Clin Exp Pathol. 2015; 8(5):4725-4734.

[145] Ganesan D, Albert A, Paul E, et al. Rutin ameliorates metabolic acidosis and fibrosis in alloxan induced diabetic nephropathy and cardiomyopathy in experimental rats. Mol Cell Biochem. 2020; 471(1-2):41-50. https://doi.org/10.1007/s11010-020-03758-y.

[146] Majid A, Hamid N, Shadan S, et al. Daidzein mitigates oxidative stress and inflammation in the injured kidney of ovariectomized rats: AT1 and Mas receptor functions. Iran J Kidney Dis. 2022; 16(1):32-43. https://doi.org/10.52547/ijkd.16.1.32.

[147] Majid A, Hamid N, Shadan S, et al. Isoflavone daidzein ameliorates renal dysfunction and fibrosis in a postmenopausal rat model: intermediation of angiotensin AT1 and Mas receptors and microRNAs 33a and 27a. Iran J Basic Med Sci. 2022; 25(11):1317-1325. https://doi.org/10.22038/IJBMS.2022.66619.14270.

[148] Biyu H, Ma P, Yang X, et al. In silico prediction and experimental validation to reveal the protective mechanism of puerarin against excessive extracellular matrix accumulation through inhibiting ferroptosis in diabetic nephropathy. J Ethnopharmacol. 2023; 319:117281. https://doi.org/10.1016/j.jep.2023.117281.

[149] Jian J, Wang D, Xiong Y, et al. Puerarin alleviated oxidative stress and ferroptosis during renal fibrosis induced by ischemia/reperfusion injury via TLR4/Nox4 pathway in rats. Acta Cir Bras. 2023; 38:e382523. https://doi.org/10.1590/acb382523.

[150] Zhu Q, Yang S, Wei C, et al. Puerarin attenuates diabetic kidney injury through interaction with guanidine nucleotide-binding protein Gi subunit alpha-1 (Gnai1) subunit. J Cell Mol Med. 2022; 26(14):3816-3827. https://doi.org/10.1111/jcmm.17414.

[151] Yang J, Li B, Wang J, et al. Puerarin alleviates chronic renal failure-induced pyroptosis in renal tubular epithelial cells by targeting miR-342-3p/TGF-β/SMAD axis. Genes Genomics. 2023; 45(12):1563-1573. https://doi.org/10.1007/s13258-023-01448-9.

[152] Wang J, Ge S, Wang Y, et al. Puerarin alleviates UUO-induced inflammation and fibrosis by regulating the NF-κB P65/STAT3 and TGFβ1/Smads signaling pathways. Drug Des Devel Ther. 2021; 15:3697-3708. https://doi.org/10.2147/DDDT.S321879.

[153] Zhou X, Bai C, Sun X, et al. Puerarin attenuates renal fibrosis by reducing oxidative stress induced-epithelial cell apoptosis via MAPK signal pathways in vivo and in vitro. Ren Fail. 2017; 39(1):423-431. https://doi.org/10.1080/0886022X.2017.1305409.

[154] Liao Y, Tan R, Li J, et al. Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting Mincle/Syk/NF-kappa B signaling pathway. Drug Des Devel Ther. 2020; 14:1455-1468. https://doi.org/10.2147/DDDT.S243420.

[155] Atteia HH, Alamri ES, Sirag N, et al. Soluble guanylate cyclase agonist, isoliquiritigenin attenuates renal damage and aortic calcification in a rat model of chronic kidney failure. Life Sci. 2023; 317:121460. https://doi.org/10.1016/j.lfs.2023.121460.

[156] Lin C, Lin Y, Paul CR, et al. Isoliquiritigenin ameliorates advanced glycation end-products toxicity on renal proximal tubular epithelial cells. Environ Toxicol. 2022; 37(8):2096-2102. https://doi.org/10.1002/tox.23553.

[157] Sun L, Yang Z, Zhang J, et al. Isoliquiritigenin attenuates acute renal injury through suppressing oxidative stress, fibrosis and JAK2/STAT3 pathway in streptozotocin-induced diabetic rats. Bioengineered. 2021; 12(2):11188-11200. https://doi.org/10.1080/21655979.2021.2006978.

[158] Huang X, Shi Y, Chen H, et al. Isoliquiritigenin prevents hyperglycemia-induced renal injuries by inhibiting inflammation and oxidative stress via SIRT1-dependent mechanism. Cell Death Dis. 2020; 11(12):1040. https://doi.org/10.1038/s41419-020-03242-5.

[159] Maugeri A, Lombardo GE, Cirmi S, et al. Pharmacology and toxicology of tannins. Arch Toxicol. 2022; 96(5):1257-1277. https://doi.org/10.1007/s00204-022-03250-0.

[160] Huang J, Zaynab M, Sharif Y, et al. Tannins as antimicrobial agents: understanding toxic effects on pathogens. Toxicon. 2024; 247:107812. https://doi.org/10.1016/j.toxicon.2024.107812.

[161] Su X, Liu X, Wang S, et al. Wound-healing promoting effect of total tannins from Entada phaseoloides (L.) Merr. in rats. Burns. 2017; 43(4):830-838. https://doi.org/10.1016/j.burns.2016.10.010.

[162] Yousuf MJ, Vellaichamy E. Protective activity of gallic acid against glyoxal-induced renal fibrosis in experimental rats. Toxicol Rep. 2015; 2:1246-1254. https://doi.org/10.1016/j.toxrep.2015.07.007.

[163] Arfian N, Wahyudi DAP, Zulfatina IB, et al. Chlorogenic acid attenuates kidney ischemic/reperfusion injury via reducing inflammation, tubular injury, and myofibroblast formation. Biomed Res Int. 2019; 2019:1-10. https://doi.org/10.1155/2019/3834802.

[164] Zhou X, Zhang B, Zhao X, et al. Chlorogenic acid prevents hyperuricemia nephropathy via regulating TMAO-related gut microbes and inhibiting the PI3K/AKT/mTOR pathway. J Agric Food Chem. 2022; 70(33):10182-10193. https://doi.org/10.1021/acs.jafc.2c03099.

[165] Gao Y, Nan Z. Mechanistic insights into the use of rhubarb in diabetic kidney disease treatment using network pharmacology. Medicine. 2022; 101(1):e28465. https://doi.org/10.1097/MD.0000000000028465.

[166] Fu S, Zhou Y, Hu C, et al. Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy. BMC Complement Med Ther. 2022; 22(1):210. https://doi.org/10.1186/s12906-022-03662-6.

[167] Verma A, Wilson PC. Advances in single-cell sequencing and spatial profiling of kidney disease. Am J Pathol. 2025; 195(1):5-6. https://doi.org/10.1016/j.ajpath.2024.10.010.

[168] Shi X, Yin H, Shi X. Bibliometric analysis of literature on natural medicines against chronic kidney disease from 2001 to 2024. Phytomedicine. 2025; 138:156410. https://doi.org/10.1016/j.phymed.2025.156410.

[169] Simeri A, Pezzi G, Arena R, et al. Artificial intelligence in chronic kidney diseases: methodology and potential applications. Int Urol Nephrol. 2025; 57(1):159-168. https://doi.org/10.1007/s11255-024-04026-6.

[170] Wen Y, Yan P, Fan P, et al. The application of rhubarb concoctions in traditional Chinese medicine and its compounds, processing methods, pharmacology, toxicology and clinical research. Front Pharmacol. 2024; 15:1376457. https://doi.org/10.3389/fphar.2024.1376457.

[171] Zhao D, Feng S, Zhang H, et al. Pharmacokinetics, tissue distribution and excretion of five rhubarb anthraquinones in rats after oral administration of effective fraction of anthraquinones from Rheum officinale. Xenobiotica. 2021; 51(8):916-925. https://doi.org/10.1080/00498254.2021.1940353.

[172] Feng SX, Li JS, Qu LB, et al. Comparative pharmacokinetics of five rhubarb anthraquinones in normal and thrombotic focal cerebral ischemia-induced rats. Phytother Res. 2013; 27(10):1489-1494. https://doi.org/10.1002/ptr.4890.

[173] Islam A, Sakamoto T, Zhai Q, et al. Application of AP-MALDI imaging mass microscope for the rapid mapping of imipramine, chloroquine, and their metabolites in the kidney and brain of wild-type mice. Pharmaceuticals. 2022; 15(11):1314. https://doi.org/10.3390/ph15111314.

[174] Li H, Ouyang Y, Lv H, et al. Nanoparticle-mediated Klotho gene therapy prevents acute kidney injury to chronic kidney disease transition through regulating PPARα signaling in renal tubular epithelial cells. Biomaterials. 2025; 315:122926. https://doi.org/10.1016/j.biomaterials.2024.122926.

[175] Zeng Y, Deng X, Shen L, et al. Advances in plant-derived extracellular vesicles: isolation, composition, and biological functions. Food Funct. 2024; 15(23):11319-11341. https://doi.org/10.1039/D4FO01871H.

[176] Fang C, Zhu X, Zhang Y, et al. Combination of allopurinol with Dahuang Mudan Tang significantly improve kidney function and alleviate oxidative stress and inflammation of chronic kidney disease stage I-III patients with hyperuricemia. J Tradit Chin Med. 2024; 44(1):182-187. https://doi.org/10.1016/j.jtcm.2023.10.006.

[177] Zheng Y, Cai GY, He LQ, et al. Efficacy and safety of Niaoduqing Particles for delaying moderate-to-severe renal dysfunction: a randomized, double-blind, placebo-controlled, multicenter clinical study. Chin Med J (Engl). 2017; 130(20):2402-2409. https://doi.org/10.4103/0366-6999.216407.

[178] Zheng Y, Wang NS, Liu YN, et al. Effects of Niaoduqing Particles on delaying progression of renal dysfunction: a post-trial, open-label, follow-up study. Chin J Integr Med. 2019; 25(3):168-174. https://doi.org/10.1007/s11655-018-2998-y.

[179] Chen H, Lin Y, Han Y, et al.A Chinese patent medicine’s long-term efficacy on non-dialysis patients with CKD stages3-5: a retrospective cohort study. Front Pharmacol. 2024; 15:1379338. https://doi.org/10.3389/fphar.2024.1379338.

[180] Wei Z, Li Q, Han X, et al. Retrospective study on the effect of Niaoduqing Particles on outcome of non-diabetic patients with stage IV chronic kidney disease. Medicine. 2024; 103(6):e37051. https://doi.org/10.1097/MD.0000000000037051.

[181] Song Z, Qin T, Pan Y, et al. Shenkang Injection improves coagulation in patients with chronic kidney disease: a systematic review and meta-analysis. J Tradit Chin Med. 2019; 39(4):451-458. https://doi.org/10.1016/j.jtcm.2019.06.003.

[182] Liu C, Liu J, Zheng Y, et al. Subchronic oral toxicity study of rhubarb extract in Sprague-Dawley rats. Regul Toxicol Pharmacol. 2021; 123:104921. https://doi.org/10.1016/j.yrtph.2021.104921.

[183] Liu Q, Yue L, Deng J, et al. Progress and breakthroughs in human kidney organoid research. Biochem Biophys Rep. 2024; 39:101736. https://doi.org/10.1016/j.bbrep.2024.101736.

[184] Yang H, Li J, Wang Z, et al. Bridging the organoid translational gap: integrating standardization and micropatterning for drug screening in clinical and pharmaceutical medicine. Life Med. 2024; 3(2):lnae016. https://doi.org/10.1093/lifemedi/lnae016.

[185] Caetano-Pinto P, Nordell P, Nieskens T, et al. Amplifying the impact of kidney microphysiological systems: predicting renal drug clearance using mechanistic modelling based on reconstructed drug secretion. ALTEX. 2023; 40(3):408-424. https://doi.org/10.14573/altex.2209131.

[186] Mahadeo A, Yeung CK, Himmelfarb J, et al. Kidney microphysiological models for nephrotoxicity assessment. Curr Opin Toxicol. 2022; 30:100341. https://doi.org/10.1016/j.cotox.2022.03.002.